Correction: PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia (PLoS ONE (2014) 9, 3, (e88298) DOI: 10.1371/journal.pone.0088298);PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Huang, Fang Fang ^a   Zhang, Li ^b   Wu, Deng Shu ^a   Yuan, Xiao Yu ^a   Chen, Fang Ping ^a   Zeng, Hui ^a   Yu, Yan Hui ^a   Zhao, Xie Lan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PTEN PROTEIN, HUMAN; TUMOR PROTEIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; S PHASE CELL CYCLE CHECKPOINT; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; AGED; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; K562 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL SURVIVAL; CHROMONES; ENZYME INHIBITORS; FEMALE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MITOXANTRONE; MORPHOLINES; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; SIROLIMUS; YOUNG ADULT;

EID: 84897406427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099917     Document Type: Erratum

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25: 85-109.
3. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082.
5. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653. (Pubitemid 40446252)
6. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, et al. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546. (Pubitemid 350159618)
7. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, et al. (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309-2315. (Pubitemid 47523149)
8. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, et al. (2005) Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11: 3425-3432. (Pubitemid 40627896)
9. Albano F, Anelli L, Zagaria A, Coccaro N, D'Addabbo P, et al. (2010) Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia. Oncogene 29: 2509-2516.
10. Barnes DJ, Schultheis B, Adedeji S, Melo JV (2005) Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24: 6432-6440. (Pubitemid 41486476)
11. Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, et al. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with upregulation of expression of interleukin-3. Blood 97: 720-728. (Pubitemid 32113406)
12. Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739-3745. (Pubitemid 39564452)
13. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, et al. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942. (Pubitemid 39434984)
14. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15665-15670. (Pubitemid 29018757)
15. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034. (Pubitemid 32937383)
16. Ross DD, Nakanishi T (2010) Impact of breast cancer resistance protein on cancer treatment outcomes. Methods Mol Biol 596: 251-290.
17. Doyle L, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358. (Pubitemid 37487163)
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947. (Pubitemid 27148818)
19. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, et al. (1995) Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 55: 1922-1926.
20. Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jensen K (1998) Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 91: 4388-4390. (Pubitemid 28262006)
21. Peng C, Chen Y, Yang Z, Zhang H, Osterby L, et al. (2010) PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115: 626-635.
22. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, et al. (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
23. Goodell MA (2005) Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr Protoc Cytom Chapter 9: Unit9 18.
24. Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 6: 231-238. (Pubitemid 37493779)
25. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, et al. (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18: 401-408. (Pubitemid 38425851)
26. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, et al. (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65: 1485-1495. (Pubitemid 38668306)
27. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, et al. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333-2337. (Pubitemid 38523883)
28. Nakanishi T, Shiozawa K, Hassel BA, Ross DD (2006) Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108: 678-684. (Pubitemid 44061370)
29. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC (2006) Functional ABCG2 is overexpressed on primary CML CD34 + cells and is inhibited by imatinib mesylate. Blood 108: 1370-1373. (Pubitemid 44232038)
30. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, et al. (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441: 518-522. (Pubitemid 44050154)
31. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482. (Pubitemid 44050144)
32. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
33. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551. (Pubitemid 43882350)
34. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, et al. (2009) Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23: 1999-2006.
35. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042. (Pubitemid 32267973)
36. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205. (Pubitemid 39297882)
37. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, et al. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707. (Pubitemid 36857723)
38. Zeng H, Park JW, Guo M, Lin G, Crandall L, et al. (2009) Lack of ABCG2 expression and side population properties in human pluripotent stem cells. Stem Cells 27: 2435-2445.
39. Li H, Gao Q, Guo L, Lu SH (2011) The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 11: 950-958.
40. Hegedus C, Truta-Feles K, Antalffy G, Brozik A, Kasza I, et al. (2012) PI3- kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter. Biochem Biophys Res Commun 420: 869-874.
41. Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, et al. (2013) Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 336: 96-105.
42. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, et al. (1997) Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3: 1337-1345. (Pubitemid 28011033)